XML 40 R29.htm IDEA: XBRL DOCUMENT v3.25.3
Stockholders’ Equity (Tables)
 9 Months Ended
Oct. 03, 2025
Share-Based Payment Arrangement [Abstract]  
Schedule of Allocated Stock-Based Compensation
We allocated the stock-based compensation for our 2017 Plan and our 2000 Employee Stock Purchase Plan (as amended and restated, the Amended ESPP) as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2025202420252024
Research and development$10,353 $8,764 $34,018 $21,834 
Selling, general and administrative20,532 14,259 58,868 45,656 
Total stock-based compensation$30,885 $23,023 $92,886 $67,490 
Stock-based compensation for each type of award under our 2017 Plan and Amended ESPP were as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2025202420252024
Stock options$493 $1,397 $2,224 $4,659 
Restricted stock units29,660 20,626 87,388 58,224 
Performance stock units— 370 241 2,194 
Employee stock purchase plan
732 630 3,033 2,413 
Total stock-based compensation$30,885 $23,023 $92,886 $67,490 
Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions
We used a Monte Carlo simulation model and the following weighted-average assumptions to determine the weighted average grant date fair value of $47.58 per share for the 2025 TSR-based RSUs and $25.26 per share for the 2025 stock price target-based RSUs:
2025 TSR-based RSUs2025 stock price target-based RSUs
Fair value of Exelixis common stock on grant date
$37.53 $37.09 
Expected volatility
32.6%38.3%
Risk-free interest rate
4.0%3.9%
Dividend yield
—%—%